Martinez Jason B, Moos Daniel D, Dahlen Larry L
Kearney Anesthesia Associates, PC, Kearney, NE 68847, USA.
J Perianesth Nurs. 2006 Apr;21(2):82-7. doi: 10.1016/j.jopan.2006.02.002.
The Food and Drug Administration (FDA) issued a letter to health care providers on December 4, 2001, concerning the medication, droperidol. The purpose of the warning was to alert health care providers to the possible role of droperidol in the development of torsades de pointes (TdP) in susceptible patients. The purpose of this article is to explore the role of droperidol in the development of TdP in susceptible patients and current recommendations for the use of droperidol as an antiemetic.
2001年12月4日，美国食品药品监督管理局（FDA）致函医疗服务提供者，内容涉及药物氟哌利多。该警告的目的是提醒医疗服务提供者注意氟哌利多在易感患者发生尖端扭转型室性心动过速（TdP）中可能起到的作用。本文的目的是探讨氟哌利多在易感患者发生TdP中所起的作用以及目前将氟哌利多用作止吐药的建议。
